ASH 2023 | The use of BTK inhibitors in R/R and treatment-naïve patients with WM
Jeffrey Matous, MD, Colorado Blood Cancer Institute, Denver, CO, discusses the use of BTK inhibitors (BTKi’s) in the management of Waldenström’s macroglobulinemia (WM). The MYD88 (L265P) mutations present in WM mean that it is sensitive to BTKi treatment, and these agents have shown promising outcomes with manageable side effects in both relapsed/refractory (R/R) and treatment-naïve disease. BTKi treatment regimens provide an alternative therapeutic option for patients with R/R WM who have failed on chemoimmunotherapy, treatment-naïve patients who are not eligible for chemoimmunotherapy, and patients who want to pursue a continuous therapy option. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Membership on Board of Directors or advisory committee: BeiGene, Pharmacyclics
WM advisory Board: BeiGene, Pharmacyclics
Consultancy and educational talks to staff: Janssen
